JOURNAL OF HEALTHCARE SCIENCES
Volume 4 Issue 12 2024, Article ID: JOHS2024001018
http://dx.doi.org/10.52533/JOHS.2024.41255
e-ISSN: 1658-8967

*Review*

# Evaluating the Impact of Drug-Drug Interactions in Polypharmacy Strategies for Safe Medication Management

Sharifah Mansour AlJassas[1*], Naif Abdullah Alzaidi[2], Sadeq Mansour Algharqan[3], Saeed Hasan Aljawad[4], Basem Modheef Alsofyani[5], Fatimah Ali Hadadi[6]

[1] *Pharmacy Department, Tumair General Hospital, Riyadh, Saudi Arabia*
[2] *Pharmacy Department, Maysan General Hospital, Taif, Saudi Arabia*
[3] *Pharmacy Department, Ministry of Health, Dammam, Saudi Arabia*
[4] *Pharmacy Department, Eradah Mental Health Complex, Dammam, Saudi Arabia*
[5] *Pharmacy Department, Ministry of Health, Taif, Saudi Arabia*
[6] *Pharmacy Department, Jazan University Hospital, Jazan, Saudi Arabia*

Correspondence should be addressed to **Sharifah Mansour AlJassas**, Pharmacy Department, Tumair General Hospital, Riyadh, Saudi Arabia. Email: shosho_s9@hotmail.com



Received: 16 December 2024, Reviewed: 29 December 2024, Accepted: 31 December 2024, Published: 31 December 2024.

**Abstract**

Polypharmacy, a common practice in managing complex and chronic medical conditions, is often accompanied by significant risks of drug-drug interactions (DDIs). These interactions can result in adverse clinical outcomes, including reduced therapeutic efficacy, toxicity, and increased hospitalization rates, especially in vulnerable populations such as older adults and patients with multimorbidities. The mechanisms underlying DDIs are multifaceted, involving both pharmacokinetic alterations, such as enzyme induction or inhibition, and pharmacodynamic interactions, which may lead to additive or antagonistic effects. Risk factors include patient-specific variables like age, genetic predispositions, and organ function, as well as systemic issues such as fragmented care and inconsistent medication monitoring. To address these challenges, healthcare systems are employing strategies that prioritize safety and efficacy. Comprehensive medication reviews conducted by pharmacists are pivotal in identifying high-risk combinations and deprescribing unnecessary medications. Technological advancements, including clinical decision support systems integrated with electronic health records, enhance the ability to detect and prevent DDIs in real-time. Furthermore, interdisciplinary collaboration among healthcare providers fosters a more cohesive approach to managing complex medication regimens. Patient education is equally crucial, emphasizing the importance of adherence and awareness of potential interactions with over-the-counter drugs and supplements. Emerging tools, such as pharmacogenomics, offer promising opportunities for personalized medication management, tailoring treatments to individual genetic profiles to minimize interaction risks. Despite progress, barriers such as limited integration of technologies and variations in provider training persist, necessitating continuous research and refinement of these strategies to ensure optimal patient outcomes.

**Keywords**: *Polypharmacy, drug-drug interactions, medication safety, clinical decision support,* pharmacogenomics

## Introduction

Polypharmacy, defined as the concurrent use of multiple medications, is a growing phenomenon driven by aging populations and the increasing prevalence of chronic diseases. While polypharmacy can be necessary for the effective management of comorbidities, it carries significant risks, notably drug-drug interactions (DDIs). DDIs occur when the pharmacological effects of one drug are altered by the presence of another, potentially leading to adverse outcomes such as toxicity, reduced therapeutic efficacy, or increased healthcare costs (1). The rising complexity of medication regimens exacerbates the potential for harmful interactions, particularly among older adults who often manage multiple chronic conditions. This demographic frequently experiences adverse drug reactions due to DDIs, which are responsible for up to 30% of hospital admissions in elderly populations (2). Such outcomes underline the critical need for safer medication practices in polypharmacy contexts.

The mechanisms of DDIs include pharmacokinetic alterations, such as changes in absorption, distribution, metabolism, and excretion, as well as pharmacodynamic interactions that may enhance or diminish the intended effects of medications. For instance, the co-administration of drugs metabolized by the same cytochrome P450 (CYP450) enzyme pathway is a common source of interaction, necessitating careful monitoring and dosage adjustments (3). Clinicians face significant challenges in predicting and managing these interactions, especially with the introduction of new pharmaceuticals and the complexity of individual patient profiles.

Efforts to mitigate these risks include the development of clinical decision support systems, comprehensive medication reviews, and patient education initiatives. These strategies aim to balance the therapeutic benefits of polypharmacy with the imperative of minimizing harm. Research has shown that tailored interventions, such as deprescribing and interdisciplinary care models, can effectively reduce the incidence of severe DDIs without compromising clinical outcomes (4). Despite advancements in understanding DDIs, gaps remain in integrating this knowledge into routine clinical practice.

## Review

Polypharmacy poses significant challenges in clinical practice, particularly due to the prevalence of DDIs, which are a primary cause of adverse drug events and medication-related hospitalizations. Managing these interactions requires a thorough understanding of both pharmacokinetic and pharmacodynamic principles, alongside patient-specific factors such as age, comorbidities, and genetic variability. Recent studies highlight the role of electronic prescribing systems and decision support tools in identifying potential DDIs before they cause harm. These technologies enable healthcare providers to assess risk factors dynamically and recommend safer alternatives or dose adjustments to mitigate adverse outcomes (5). However, barriers to the effective management of DDIs persist. Limited integration of comprehensive interaction databases into routine healthcare workflows, along with varying levels of provider awareness, exacerbates the risk. Additionally, the rapid introduction of new pharmaceuticals complicates efforts to stay abreast of all potential interactions. Efforts to reduce polypharmacy risks have focused on interdisciplinary approaches, such as involving pharmacists in medication reviews and employing deprescribing protocols. These strategies not only reduce DDI prevalence but also enhance medication adherence and patient outcomes (6). Addressing these challenges requires continued research, education, and system-wide adoption of evidence-based practices to ensure safer medication management.

### *Mechanisms and Risk Factors of Drug-Drug Interactions in Polypharmacy*

DDIs in the context of polypharmacy are primarily driven by pharmacokinetic and pharmacodynamic mechanisms, exacerbated by patient-specific variables and systemic healthcare challenges. Pharmacokinetically, DDIs often arise from alterations in drug metabolism mediated by the


http://dx.doi.org/10.52533/JOHS.2024.41255

CYP450 enzyme family. These enzymes metabolize the majority of prescription drugs, and their inhibition or induction can result in elevated plasma drug concentrations or diminished therapeutic efficacy. For instance, inhibitors of CYP3A4, such as certain antifungals, can dangerously elevate statin levels, increasing the risk of myopathy (7). Age-related reductions in hepatic and renal function further exacerbate these risks, complicating the pharmacokinetics of metabolized drugs (8).

Pharmacodynamic interactions involve additive, synergistic, or antagonistic effects between drugs acting on the same physiological pathways. A notable example is the increased bleeding risk associated with the combined use of anticoagulants and non-steroidal anti-inflammatory drugs (9). Similarly, overlapping central nervous system depressants, such as benzodiazepines and opioids, have been implicated in respiratory depression and increased mortality rates, particularly among older adults (10). These interactions highlight the intricate balance required to optimize therapeutic outcomes while avoiding adverse events. Patient-related factors are critical in the prevalence of DDIs. Older adults are disproportionately affected due to higher rates of polypharmacy and age-related changes in drug absorption, metabolism, and excretion (11). Genetic polymorphisms further influence individual drug responses, with variants in genes encoding CYP450 enzymes altering susceptibility to DDIs (3). Chronic conditions such as diabetes, hypertension, and cardiovascular disease necessitate complex regimens, further compounding the risk of interactions (12).

Systemic healthcare challenges exacerbate these risks. Fragmentation of care, where multiple specialists manage the same patient independently, is a significant contributor. This lack of coordination often results in overlapping prescriptions that go unnoticed in the absence of robust medication reconciliation systems (13). For instance, patients transitioning between inpatient and outpatient care are particularly vulnerable to DDIs due to the involvement of multiple prescribers (6). The lack of comprehensive electronic prescribing tools in many healthcare settings further limits the ability of clinicians to identify and prevent interactions effectively (6). Healthcare professionals, particularly pharmacists, play a pivotal role in mitigating DDIs. Pharmacists conducting medication reviews have been shown to significantly reduce the incidence of clinically significant interactions (14). Collaborative care models, where pharmacists work alongside physicians, enhance the safety of complex medication regimens. Educational interventions targeting both providers and patients further improve adherence to safer prescribing practices and increase awareness of high-risk drug combinations (15).

Emerging technologies provide additional tools for addressing DDIs. Clinical decision support systems integrated into electronic health records enable real-time alerts for potential interactions during prescribing, improving clinician decision-making (16). Advances in pharmacogenomics offer promising avenues for tailoring therapies to genetic profiles, potentially reducing interaction risks by predicting individual drug responses (10). Despite their promise, these technologies face barriers such as cost, accessibility, and variability in implementation across healthcare systems (5).

### *Clinical Outcomes and Challenges in Managing Drug-Drug Interactions*

The clinical consequences of DDIs in polypharmacy are wide-ranging, encompassing reduced therapeutic efficacy, increased toxicity, and heightened risk of hospitalization. Anticoagulants and antiplatelet agents exemplify this dynamic, as their combined use often leads to excessive bleeding risks that complicate cardiovascular disease management (16). Such interactions necessitate careful therapeutic balancing, particularly in patients with coexisting comorbidities.

Elderly populations are particularly susceptible to DDIs due to physiological changes such as impaired renal and hepatic function, which alter the pharmacokinetics of many drugs. The diminished clearance of medications in older adults elevates the risk of adverse drug events (10). In oncology, DDIs have been observed to interfere with


http://dx.doi.org/10.52533/JOHS.2024.41255

chemotherapeutic efficacy, complicating the already-challenging management of cancer patients with multimorbidity (4). Such outcomes emphasize the critical need for proactive DDI identification and prevention strategies in vulnerable patient groups.

The fragmented nature of healthcare systems presents significant challenges to managing DDIs effectively. Transitions of care—such as hospital discharges—often lead to incomplete or inaccurate medication reconciliation, creating opportunities for harmful interactions. Studies report that a significant proportion of patients experience medication discrepancies at discharge, with many involving clinically relevant DDIs (4). This underscores the importance of robust coordination among healthcare providers and the integration of reliable decision-support tools into prescribing practices. Patient-related factors further exacerbate these challenges. Low health literacy and inadequate understanding of medication regimens contribute to poor adherence, increasing the likelihood of interactions. The unregulated use of over-the-counter drugs and supplements compounds the problem. For instance, the widespread use of herbal remedies like St. John's Wort, which induces cytochrome P450 enzymes, has been shown to reduce the efficacy of critical medications, including anticoagulants and antiretrovirals (16).

Efforts to mitigate DDIs must prioritize comprehensive medication reviews, deprescribing practices, and interdisciplinary collaboration. Pharmacists, in particular, are crucial in identifying high-risk drug combinations and educating patients about potential interactions. Emerging tools such as pharmacogenomic testing hold promise for tailoring medication regimens to individual genetic profiles, reducing the likelihood of harmful interactions while improving therapeutic outcomes (10). By addressing these multifaceted challenges, healthcare systems can better manage the complexities of DDIs and ensure safer polypharmacy practices.

### *Strategies for Mitigating Risks and Enhancing Safe Medication Practices*

Effective strategies to mitigate DDIs in polypharmacy and enhance medication safety hinge on a multifaceted approach incorporating clinical, technological, and patient-centered interventions. Comprehensive medication reviews, particularly by pharmacists, are instrumental in identifying potential DDIs. Pharmacists play a critical role in deprescribing unnecessary medications and optimizing therapeutic regimens for safety and efficacy (17). For example, when managing chronic conditions, medication reviews can highlight overlapping mechanisms of action that elevate the risk of adverse outcomes, providing opportunities for safer substitutions or dose adjustments.

Clinical decision support systems (CDSS) have become an essential tool for mitigating risks associated with DDIs. Integrated into electronic health records, CDSS provides automated alerts during the prescribing process to flag potentially harmful interactions (18). These systems are most effective when they are tailored to reduce "alert fatigue" by prioritizing high-risk interactions. Incorporating real-time pharmacogenomic data into CDSS further enhances their utility by personalizing recommendations based on individual patient genetic profiles. Another critical intervention involves interdisciplinary collaboration between healthcare professionals, including physicians, pharmacists, and nurses. Interdisciplinary care models ensure comprehensive assessments of patient medication regimens, addressing gaps in care that arise from fragmented healthcare systems. Studies demonstrate that team-based approaches significantly reduce prescribing errors and improve patient outcomes, particularly in complex cases involving multiple providers (19).

Patient education is a cornerstone of medication safety. Empowering patients to understand their medication regimens and potential risks associated with over-the-counter drugs and supplements is vital. Educational programs that emphasize clear communication between patients and providers foster adherence and encourage reporting of side effects. Such programs have been particularly


http://dx.doi.org/10.52533/JOHS.2024.41255

effective in reducing interactions involving commonly used substances like St. John's Wort, which interacts with numerous prescription medications by inducing metabolic enzymes (20).

## Conclusion

In addressing the complexities of drug-drug interactions in polypharmacy, an integrated approach combining clinical vigilance, advanced decision-support systems, and patient education is essential. Collaboration among healthcare professionals and personalized interventions, such as pharmacogenomics, significantly enhances medication safety. By prioritizing proactive measures and fostering interdisciplinary care, healthcare systems can mitigate the risks associated with polypharmacy and improve patient outcomes. Continuous research and innovation remain vital to refining these strategies and ensuring their widespread adoption.

## Disclosure

### *Conflict of interest*

There is no conflict of interest.

### *Funding*

No funding.

### *Ethical consideration*

Non applicable.

### *Data availability*

Data that support the findings of this study are embedded within the manuscript.

### *Author contribution*

All authors contributed to conceptualizing, data drafting, collection and final writing of the manuscript.

## References

1. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC medicine. 2015;13:1-10.

2. Salwe KJ, Kalyansundaram D, Bahurupi Y. A study on polypharmacy and potential drug-drug interactions among elderly patients admitted in department of medicine of a tertiary care hospital in Puducherry. Journal of clinical and diagnostic research: JCDR. 2016;10(2):FC06.

3. Schneider KL, Kastenmüller K, Weckbecker K, Bleckwenn M, Böhme M, Stingl JC. Potential drug-drug interactions in a cohort of elderly, polymedicated primary care patients on antithrombotic treatment. Drugs & Aging. 2018;35:559-68.

4. Marengoni A, Onder G. Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity. British Medical Journal Publishing Group; 2015.

5. Rodrigues MCS, Oliveira Cd. Drug-drug interactions and adverse drug reactions in polypharmacy among older adults: an integrative review. Revista latino-americana de enfermagem. 2016;24:e2800.

6. Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C. Prevalence and risk of potential cytochrome p450–mediated drug-drug interactions in older hospitalized patients with polypharmacy. Annals of Pharmacotherapy. 2013;47(3):324-32.

7. Deodhar M, Al Rihani SB, Arwood MJ, Darakjian L, Dow P, Turgeon J, et al. Mechanisms of CYP450 inhibition: understanding drug-drug interactions due to mechanism-based inhibition in clinical practice. Pharmaceutics. 2020;12(9):846.

8. Janković SM, Pejčić AV, Milosavljević MN, Opančina VD, Pešić NV, Nedeljković TT, et al. Risk factors for potential drug-drug interactions in intensive care unit patients. Journal of critical care. 2018;43:1-6.

9. Veloso RCdSG, Figueredo TPd, Barroso SCC, Nascimento MMGd, Reis AMM. Factors associated with drug interactions in elderly hospitalized in high complexity hospital. Ciencia & saude coletiva. 2019;24:17-26.

10. Papotti B, Marchi C, Adorni MP, Potì F. Drug-drug interactions in polypharmacy patients: The


http://dx.doi.org/10.52533/JOHS.2024.41255

impact of renal impairment. Current research in pharmacology and drug discovery. 2021;2:100020.

11. Sommer J, Seeling A, Rupprecht H. Adverse drug events in patients with chronic kidney disease associated with multiple drug interactions and polypharmacy. Drugs & aging. 2020;37:359-72.

12. Bojuwoye AO, Suleman F, Perumal-Pillay VA. Polypharmacy and the occurrence of potential drug–drug interactions among geriatric patients at the outpatient pharmacy department of a regional hospital in Durban, South Africa. Journal of pharmaceutical policy and practice. 2022;15:1-12.

13. Das B, Ramasubbu SK, Agnihotri A, Kumar B, Rawat VS. Leading 20 drug–drug interactions, polypharmacy, and analysis of the nature of risk factors due to QT interval prolonging drug use and potentially inappropriate psychotropic use in elderly psychiatry outpatients. Therapeutic Advances in Cardiovascular Disease. 2021;15:17539447211058892.

14. Trevisan C, Limongi F, Siviero P, Noale M, Cignarella A, Manzato E, et al. Mild polypharmacy and MCI progression in older adults: the mediation effect of drug–drug interactions. Aging Clinical and Experimental Research. 2021;33:49-56.

15. Georgiev KD, Hvarchanova N, Stoychev E, Kanazirev B. Prevalence of polypharmacy and risk of potential drug-drug interactions among hospitalized patients with emphasis on the pharmacokinetics. Science Progress. 2022;105(1):00368504211070183.

16. Corsonello A, Abbatecola AM, Fusco S, Luciani F, Marino A, Catalano S, et al. The impact of drug interactions and polypharmacy on antimicrobial therapy in the elderly. Clinical Microbiology and Infection. 2015;21(1):20-6.

17. Bates DW, Leape LL, Cullen DJ, Laird N, Petersen LA, Teich JM, et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. Jama. 1998;280(15):1311-6.

18. Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An overview of clinical decision support systems: benefits, risks, and strategies for success. NPJ digital medicine. 2020;3(1):17.

19. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA internal medicine. 2015;175(5):827-34.

20. Alosaimy S, Vaidya A, Day K, Stern G. Effect of a pharmacist-driven medication management intervention among older adults in an inpatient setting. Drugs & aging. 2019;36:371-8.


http://dx.doi.org/10.52533/JOHS.2024.41255